LF
ALNY icon

Lansforsakringar Fondforvaltning’s Alnylam Pharmaceuticals ALNY Stock Holding History

Lansforsakringar Fondforvaltning’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.4M Sell
41,157
-733
-2% -$221K 0.06% 266
2026
Q1 		$13.9M Sell
41,890
-450
-1% -$153K 0.07% 218
2025
Q4 		$16.8M Sell
42,340
-64
-0.2% -$28.3K 0.08% 193
2025
Q3 		$19.3M Buy
42,404
+2,173
+5% +$885K 0.1% 174
2025
Q2 		$13.1M Sell
40,231
-2,072
-5% -$573K 0.08% 225
2025
Q1 		$11.4M Sell
42,303
-241
-0.6% -$61.9K 0.07% 243
2024
Q4 		$10M Buy
+42,544
New +$11.2M 0.06% 283

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lansforsakringar Fondforvaltning's ALNY Position: Q2 2026 in Review

Lansforsakringar Fondforvaltning reduced its Alnylam Pharmaceuticals (ALNY) stake by 1.7% in Q2 2026, selling an estimated $221K and leaving 41,157 shares worth $12.4M. The position accounts for 0.06% of the portfolio, ranked #266.

Lansforsakringar Fondforvaltning first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $19.3M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Lansforsakringar Fondforvaltning held 41,157 shares of Alnylam Pharmaceuticals worth $12.4M as of Q2 2026.
  • Lansforsakringar Fondforvaltning sold 733 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $221K.
  • Alnylam Pharmaceuticals made up 0.06% of Lansforsakringar Fondforvaltning's portfolio in Q2 2026, its #266 holding.
  • Lansforsakringar Fondforvaltning first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Lansforsakringar Fondforvaltning's Alnylam Pharmaceuticals position peaked at $19.3M in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Lansforsakringar Fondforvaltning's 13F filing for Q2 2026, filed 13 Aug 2026.